A * STAR partner Roche to identify new therapeutic targets for the treatment of cancer -
Partnership with Roche Pharma Research and Early Development takes advantage of a unique find by the bioprocess a * STAR Technology Institute to develop new approaches for the detection and treatment of cancer
a * bioprocessing Technology Institute STAR (BTI) has reached an agreement with one of the largest pharmaceutical company in the world, Roche, to identify new drug candidates for the detection and treatment of cancer. The partnership brings together the BTI capabilities in the discovery of new antibodies and Roche's expertise in the development of monoclonal antibodies (mAb) therapy, opening the possibility of better treatment for cancer, a major cause of death world.
The collaboration makes use of the BTI discovery of a new mechanism in which antibodies can directly target and destroy cancer cells, has the potential for a whole new class of cancer treatment. Cancer cells can be distinguished from normal cells by high sugar levels on the cell surface. MAb and discoveries generated by BTI are able to recognize these sugar targets and enable more precise identification of cancer cells compared to traditional antibodies that target proteins. mAbs generated by BTI are also unique in having a new mechanism of action; they cause pores to form on the surface of cancer cells, leading to cell damage and eventual death of those diseased cells
Dr. Andre Choo, a principal investigator at the BTI and principal investigator for the project, declared:.
It is exciting to be able to generate a new class of mAbs that can specifically recognize sugars and lead to rapid death of diseased cells. This opens up new strategies to target and kill cancer cells.
Based on this discovery, BTI scientists have developed a mAb pipeline for major cancers found in Singapore. The partnership with Roche will new diagnostic tests and cancer treatments to grow faster and be early for patient care. These treatments could complement and enhance the drugs against cancer and the existing results in more effective and safer treatments for cancer patients
Prof Lam Kong Peng, executive director of BTI, said :.
This collaboration highlights the effectiveness of the search for BTI antibody and allows us to leverage the expertise of Roche to develop new antibody-based therapies. We are convinced that this is the beginning of a long and fruitful partnership that will not only beneficial to human health, but also the organic industry.
Dr. Juan Carlos Lopez, head of Roche Pharma Research and Early Development of academic relations and collaborations, said:
access external innovation by through partnerships with public sector research institutes is essential to identify the first class opportunities or best-in-class. Gather the expertise of BTI and expertise Roche increases the chances of success in the development of new antibody-based therapies targeting cancer and cancer stem cells that have the potential to revolutionize the way we treat cancer .
EmoticonEmoticon